ClinicalTrials.gg
CompletedNCT00308191Updated Mar 7, 2008

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

A Phase 3 interventional study of Formoterol Fumarate and Tiotropium Bromide in COPD, sponsored by Dey. Completed at 17 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2008-03-07.

Sponsored by Dey (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
44th of 89
128 · median 120
Started
2006
with 7 others
Phase 3
40 of 89
1 open now
Registered
12th of 89
by date
Lead sponsor
11 of 89
Dey

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 44th largest by enrollment, is one of 8 that started in 2006, is one of 40 in phase 3, and was the 12th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.

03

Conditions studied

  • COPD

Keywords

  • COPD
  • Formoterol
  • Tiotropium
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical diagnosis of
  • Current or prior history of cigarette smoking

Exclusion criteria

Exclusion Criteria:

  • Medical diagnosis of asthma
  • Significant condition or disease other than
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
128 participants
06

What researchers measure

Primary outcomes

  1. Measure of lung Function

Secondary outcomes

  1. Change in lung function, vital signs; physical examinations; clinical laboratory assessments; adverse event reporting; patient questionnaires

07

Study locations

17 sites
  • Research Site
    Phoenix, Arizona 85006, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Sepulveda, California 91343, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Tamarac, Florida 33321, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Ann Arbor, Michigan 48105, United States
  • Research Site
    Livonia, Michigan 48152, United States
  • Research Site
    St. Louis, Missouri 63141, United States
  • Research Site
    Liverpool, New York 13088, United States
  • Research Site
    Rochester, New York 14618, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Collegeville, Pennsylvania 19426, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    San Antonio, Texas 78229, United States
08

References and documents

Publications

  • Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008 Apr;102(4):479-87. doi: 10.1016/j.rmed.2007.12.019. Epub 2008 Feb 6. PubMed 18258423 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of May 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2006
First posted
Mar 29, 2006
Start
Apr 2006
Primary completionActual
May 2006
CompletionActual
Dec 2006
Last update
Mar 7, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00308191
Lead sponsor
Dey
First posted
Mar 29, 2006
Start date
Apr 2006
Primary completion
May 2006
Completion
Dec 2006
Last update
Mar 7, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Formoterol · Tiotropium

Start the discussion